Background-Mutations in the cardiac sodium (Na) channel gene (SCN5A) give rise to the congenital long-QT syndrome (LQT3) and the Brugada syndrome. Na channel blockade by antiarrhythmic drugs improves the QT interval prolongation in LQT3 but worsens the Brugada syndrome ST-segment elevation. Although Na channel blockade has been proposed as a treatment for LQT3, flecainide also evokes "Brugada-like" ST-segment elevation in LQT3 patients. Here, we examine how Na channel inactivation gating defects in LQT3 and Brugada syndrome elicit proarrhythmic sensitivity to flecainide. Methods and Results-We measured whole-cell Na current (I Na ) from tsA-201 cells transfected with ⌬KPQ, a LQT3 mutation, and 1795insD, a mutation that provokes both the LQT3 and Brugada syndromes. The 1795insD and ⌬KPQ channels both exhibited modified inactivation gating (from the closed state), thus potentiating tonic I Na block. Flecainide (1 mol/L) tonic block was only 16.8Ϯ3.0% for wild type but was 58.0Ϯ6.0% for 1795insD (PϽ0.01) and 39.4Ϯ8.0% (PϽ0.05) for ⌬KPQ. In addition, the 1795insD mutation delayed recovery from inactivation by enhancing intermediate inactivation, with a 4-fold delay in recovery from use-dependent flecainide block. Conclusions-We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation)
C
ardiac Na channels continuously undergo voltagedependent structural rearrangements: "activation" allows Na ϩ permeation, whereas "inactivation" processes terminate cation flux (fast inactivation) and render the channel refractory for sustained periods to restimulation (intermediate and slow inactivation). Mutations in SCN5A modify inactivation in distinctive ways to elicit either the congenital long-QT syndrome (LQT3) or the Brugada syndrome. 1, 2 In LQT3, cardiac repolarization is delayed, often through partial disruption of fast inactivation that permits a persistent inward current during the action potential plateau 3 (other mechanisms are described). 4 In contrast, Brugada syndrome is characterized by distinctive ST-segment elevations and is typically associated with mutations that enhance Na channel inactivation. [5] [6] [7] Despite their proarrhythmic potential, 8 antiarrhythmic agents with Na channel blocking (class I) activity have been widely used to treat life-threatening cardiac arrhythmias. Class I agents may be particularly useful in managing patients with LQT3 disorders 9 through blockade of the sustained inward current through the mutant channels. 10 -12 In contrast, Na channel blockade exacerbates the ECG pattern in Brugada syndrome. 13 Despite this apparent divergence between the clinical manifestations of Na channel blockade in the LQT3 and Brugada syndromes, it was recently shown that flecainide, a potent Na channel blocker, produced ST-segment elevation characteristic of Brugada syndrome in a number of LQT3 patients, 14 suggesting that Na channel blockade may have proarrhythmic potential in LQT3.
Recognizing the mechanistic role of cardiac Na channel inactivation in antiarrhythmic drug action, 15, 16 these observations suggest that LQT3 channels may possess multiple, distinct inactivation defects that evoke both antiarrhythmic and proarrhythmic flecainide sensitivity. Recently, an SCN5A mutation was identified that provokes the ECG features of both LQT3 and Brugada syndrome (1795insD) 6, 17 and worsening ST-segment elevation with Na channel blockade. 17 We exploited the unique characteristics of this channel to probe the linkage between Na channel inactivation and flecainide blockade. Our findings provide a framework for understand-ing the clinical response to flecainide on the basis of the inactivation gating defects associated with inherited SCN5A mutations.
Methods
The 1795insD and ⌬KPQ mutant channels were prepared as previously described 17, 18 and were subcloned into the expression vector pCGI (provided by David Johns, Johns Hopkins University, Baltimore, Md) for bicistronic expression of the channel protein and GFP reporter in tsA-201 cells. Cells were cotransfected with an equimolar ratio of Na channel human ␤ 1 subunit. Whole-cell Na currents were recorded at 21°C as described previously. 6 The pipette solution contained (in mmol/L) NaF 10, CsF 110, CsCl 20, EGTA 10, and HEPES 10 (pH 7.35 with CsOH); the bath solution contained NaCl 145, KCl 4, CaCl 2 1.8, MgCl 2 1, and HEPES 10 (pH 7.35). Flecainide (acetate salt) was made up in a 10-mmol/L stock solution and diluted in the bath solution (1 mol/L), and data were recorded after a 3-minute period for drug equilibration. Voltage-clamp protocols are described with each figure, results are expressed as meanϮSEM, and statistical comparisons and curve fitting were performed with Microcal Origin. Figure 1 shows the precordial leads from a 1795insD carrier who exhibited minor baseline ST-segment elevation at baseline (left). After intravenous flecainide (2 mg/kg over 10 minutes), a marked increase in ST-segment elevation ( Figure  1 , right) was observed, and the rate-corrected QT interval did not shorten (QTc remained Ϸ470 ms). We therefore examined the sensitivity of 1795insD channels to flecainide. Figure  2 shows wild-type (WT) and mutant I Na recorded from transfected tsA-201 cells after a sustained (500-ms) holding period at Ϫ100 mV; currents recorded from the same cell before and after exposure to a clinically relevant concentration of flecainide (1 mol/L) 19 are superimposed. This "tonic block" of peak I Na for 1795insD channels was markedly increased compared with WT ( Figure 2 , inset: 1795insD was 58.0Ϯ6.0% versus 16.8Ϯ3.0% for WT, PϽ0.01).
Results

Mutations Augment Closed-State Inactivation and Tonic Block
Previous studies indicate that antiarrhythmic drugs may bind avidly to the inactivated conformational state of the cardiac Na channel. 15, 16 Although cardiac Na channels typically inactivate from open states when depolarized, the channels also inactivate directly from closed (rested) states while hyperpolarized. 20 Given the observed increase in 1795insD tonic block at a relatively hyperpolarized holding potential (Figure 2) , we tested the hypothesis that LQT3 mutations may enhance inactivation from closed states at membrane potentials near V rest and thereby confer higher flecainide block sensitivity. Previous studies have demonstrated that the 1795insD mutation induces a hyperpolarizing shift in the voltage-dependence of steady-state availability, 6 a finding that could be explained by enhanced closed-state inactivation gating. To examine closed-state inactivation directly, we measured the peak I Na elicited by a test pulse to Ϫ20 mV after subthreshold depolarizations (Ϫ90 or Ϫ100 mV) of incremental duration (protocol inset, Figure 3A ). Peak I Na gradually decreased as the period of mild prepulse depolarization increased. The solid lines indicate leastsquares fits of a single exponential function (yϭy 0 ϩAe Ϫx/ ) to the data at each voltage (fitted parameters at Ϫ100 mV in Table 1 ). Relative to the peak I Na available at Ϫ120 mV, the extent of closed-state inactivation (A) was increased in 1795insD, and the rate of development of closed-state inactivation was also accelerated Ϸ3-fold ( for WT was 42.4Ϯ5.4 ms versus 12.0Ϯ0.9 ms for 1795insD, PϽ0.001). Figure 3B examines the effects of flecainide at Ϫ100 mV in the same group of cells as studied in panel A. Representative 1795insD I Na recorded before (from panel A) and after flecainide exposure are also shown superimposed for the shortest (1 ms) and longest (500 ms) prepulse to Ϫ100 mV ( Figure 3B , inset). Flecainide substantially increased the extent to which subthreshold depolarizations reduced peak I Na , and this effect was more pronounced in the mutant channel. Notably, the time constant () for reduction in peak I Na during drug exposure mirrored the values measured for closed-state inactivation in drug-free conditions (Table 1) . At Ϫ100 mV ( Figure 3B ), in flecainide was 33.8Ϯ3.6 ms for WT (PϭNS versus drug-free) and 10.9Ϯ1.7 ms for 1795insD (PϭNS versus drug-free). Hence, drug-exposed channels became unavailable, with a kinetic signature that recapitulated closed-state inactivation in drug-free conditions, sug- Tonic block of peak WT and 1795insD mutant I Na by flecainide. Representative WT and 1795insD I Na recordings in absence and presence of flecainide. I Na was elicited by a 100-ms depolarizing step from Ϫ100 to Ϫ20 mV (5-second recovery interval between depolarizations). Zero current levels are indicated by dotted lines. Inset: Summary data for flecainide % reduction of peak I Na (WT, nϭ5; 1795insD, nϭ9). *PϽ0.01.
gesting that the gating process potentiates tonic block at membrane potentials near V rest . In contrast, the duration of subthreshold depolarization had little effect on the magnitude of the 1795insD sustained-current component (I sus ), and flecainide also had no effect on I sus after either brief or prolonged prepulses ( Figure 3B , inset). I sus (nϭ8, paired, % predrug peak I Na ) was: control 3.3Ϯ0.5 and 2.8Ϯ0.6 for 1-and 500-ms prepulses, and with flecainide 2.5Ϯ0.6 and 2.3Ϯ0.5 for 1-and 500-ms prepulses (PϭNS versus control). These results suggest that unlike peak I Na , channels occupying a mode that produces sustained current 3 are less susceptible to closed-state inactivation, and consistent with this feature, are also resistant to flecainide block.
Like 1795insD patients, carriers of the LQT3 ⌬KPQ mutation have exhibited "Brugada-like" ECG changes during exposure to IV flecainide. 14 Using the same approach as shown in Figure 3 , we examined closed-state inactivation and tonic flecainide block of ⌬KPQ channels (fitted parameters, Table 1 ). Figure 4A indicates that the rate of closed-state inactivation of the ⌬KPQ channel (ϭ6.5Ϯ1 ms) was faster than WT (ϭ42.4Ϯ5.4 ms, PϽ0.001 versus ⌬KPQ). Although the extent of closed-state inactivation for ⌬KPQ was somewhat less than 1795insD (although greater than WT), the time constant of ⌬KPQ closed-state inactivation was even faster than 1795insD (PϽ0.001). Also like 1795insD, the rate at which peak I Na is suppressed at Ϫ100 mV during exposure to flecainide mirrored the rate of closed-state inactivation ( Figure 4B , Table 1 ). The findings indicate that like 1795insD, the ⌬KPQ channel is susceptible to enhanced tonic flecainide block as a result of increased closed-state inactivation gating near V rest .
Intermediate Inactivation, the Brugada Syndrome, and Drug Sensitivity
In addition to the predominant, rapid inactivation gating process that terminates I Na , depolarized Na channels may occupy one or more inactivated states that recover slowly (and incompletely) during the diastolic interval between stimuli. Recent studies have shown that Brugada syndrome mutations (both 1795insD and T1620M) exhibit excessive "intermediate" inactivation during depolarization periods rel- Figure 3 . Closed-state inactivation of 1795insD channels. Top, Cells were held at Ϫ120 mV for 5 seconds between depolarization sequences; additional experiments (not shown) using longest (500-ms) prepulse in flecainide confirm that no block accumulates between pulse sequences. A, Relative peak I Na at Ϫ20 mV is plotted as a function of prepulse duration. Closed-state inactivation is evoked by Ϫ100-or Ϫ90-mV prepulse potentials of varying duration. B, Loss of availability due to Ϫ100-mV prepulses in flecainide (1 mol/L). Inset, Representative I Na from a 1795insD cell after short (1-ms, left) and long (500-ms, right) Ϫ100-mV prepulses before (from A) and after flecainide. evant to the cardiac action potential (Ͻ1 second). 6, 7 This state, denoted "I M ," has been linked to an outer pore conformational change and exhibits a cooperative, functional linkage to use-dependent lidocaine block. 21 To examine the role of enhanced I M gating of 1795insD in use-dependent flecainide block, we first used a 2-pulse protocol, as shown in Figure 5A (inset). The duration of the first pulse (P 1 ) was varied, and the fractional reduction in peak I Na (due to I M inactivation) was recorded in a subsequent test pulse (P 2 ) after a brief, 20-ms repolarization to allow recovery from fast inactivation, but not I M . The solid lines indicate least-squares fits of a single-exponential function to the data (Table 2) ; as shown previously, 6 the amplitude of the I M component (A) was significantly greater in the mutant (0.15Ϯ0.01) than the WT (0.08Ϯ0.008, PϽ0.01). Flecainide (1 mol/L) exposure accelerated the rate () of depolarization-dependent block (Table 2 ) in 1795insD but not in WT.
Even greater differences were apparent when the timedependent recovery from I M or flecainide block was assessed ( Figure 5B) . A fixed-duration pulse (P 1 ) of 1 second to induce I M was followed by a variable-length hyperpolarization and a test pulse (P 2 ). In drug-free conditions, both WT and 1795insD exhibited 2 clear recovery components, reflecting fast and intermediate inactivation (fitted parameters, Table 3 ). As shown previously, 6 the amplitude of the slow component of recovery (A 2 ) was greater in 1795insD than WT (Table 3) . Moreover, on exposure to flecainide, the time constant for slow recovery ( 2 ) was slightly delayed for WT (Ϸ2-fold) but was markedly delayed for 1795insD (Ϸ4-fold, Table 3 , arrow in Figure 5B ). In 1 mol/L flecainide, 2 was 282.4Ϯ43 ms for 1795insD, but it was only 75.0Ϯ7.1 ms for WT (PϽ0.05). These results suggest that excessive I M occupancy has a small effect on flecainide block development (Table 2 ) but substantially slows the recovery from pulse-dependent Na channel blockade ( Figure 5B , Table 3 ). During trains of ten 1-second depolarizations ( Figure 5B, inset) , the combined 1795insD I M gating effects on development and recovery from flecainide block yielded a marked use-dependent reduction in 1795insD peak I Na . At 0.95 Hz, flecainide reduced P 2 /P 1 peak I Na over the drug-free value by 22.4Ϯ4.0% in 1795insD but only by 12.8Ϯ1.0% in WT (PϽ0.05). At a slower pulse rate (0.33 Hz), flecainide block for 1795insD still exceeded WT (19.6Ϯ3.1% in 1795insD versus 5.4Ϯ1.1% in WT, PϽ0.01). This I M -related pharmacological potentiation could further compromise Na channel availability in Brugada syndrome.
Discussion
Mechanistic overlap between the LQT3 and Brugada syndromes has been foreshadowed by recent studies linking both phenotypes to the same (1795insD) 17 or nearly adjacent SCN5A loci 22 and clinical evidence that patients harboring only LQT3 mutations develop Brugada-like ST-segment elevations when treated with flecainide. 14 Our findings identify a common component of inactivation gating dysfunction in LQT3 and Brugada syndrome (enhanced closed-state inactivation). Cardiac Na channels exhibit substantial closedstate inactivation at or below the resting membrane potential (V restϷ Ϫ90 mV), 20 and we find that both the 1795insD and ⌬KPQ mutations further enhance fast inactivation from closed states (Figures 3A and 4A) . In both mutants, flecainide Ϫt/ 1)ϩA 2 (1Ϫe Ϫt/ 2). Inset, Pulse-train protocol for assessing use-dependent block (left). In drug-free conditions, reduction in peak I Na (1ϪP 2 /P 1 ) by slow inactivation alone at 0.95 Hz (50-ms recovery between pulses) was (%) WT 26.6Ϯ3.1 (nϭ6), 1795insD 44.2Ϯ2.8 (nϭ6), and at 0.33 Hz (2-second recovery between pulses) was WT 2.2Ϯ0.5 (nϭ6), 1795insD 11.6Ϯ1.4 (nϭ6). In flecainide (1 mol/L), reduction in P 2 peak I Na relative to P 1 , due to combined effects of drug block and slow inactivation at 0.95 Hz, was (%) WT 39.4Ϯ3.3, 1795insD 66.5Ϯ3.6, and at 0.33 Hz was WT 7.6Ϯ0.9, 1795insD 29Ϯ2.5. Bar graph (right) shows reduction in P 2 I Na relative to P 1 in drug minus drug-free measurement (in each cell, at both stimulus rates), indicating extent of use-dependent I Na suppression by flecainide over and above that accounted for by gating (slow inactivation) alone. *PϽ0.05. block increased with mild depolarization (below the activation threshold), with kinetic characteristics that recapitulated closed-state inactivation ( Figures 3B and 4B) , suggesting that the excess tonic block observed for ⌬KPQ or 1795insD at V rest is attributable to increased closed-state inactivation. In the myocardium, a number of conditions (mutations, drugs, ischemia, etc) substantially reduce peak I Na and may precipitate ECG changes that recapitulate the Brugada syndrome. 23, 24 While providing a mechanistic rationale for the ECG changes evoked by flecainide in LQT3 patients, 14 our findings also support the possibility that flecainide use in LQT3 patients may have proarrhythmic risks. Previous studies of the sustained, noninactivating current (I sus ) in LQT3 have found that lidocaine and its analogues preferentially reduce I sus over peak I Na . 10, 11, 25 In contrast, 1795insD I sus was resistant to subthreshold depolarizations (unlike peak I Na ), and 1 mol/L flecainide had no effect on I sus even after a sustained prepulse ( Figure 3B, inset) . The findings are consistent with the clinical observation of absent QTc shortening during flecainide treatment of 1795insD patients (Figure 1) . At a mechanistic level, the results also suggest that 1795insD channels opening in a "bursting" mode are resistant to closed-state inactivation and are thereby insensitive to flecainide blockade. The finding that open, noninactivating channels are insensitive to drug was unexpected, given previous results from use of higher (200 mol/L) concentrations of flecainide with cloned neuronal Na channels that identify a component of open-channel block. 26 To explore this issue in more detail, we used the WT channel and rapid trains of brief pulses at 10 Hz (20 successive 50-ms steps from Ϫ120 to 0 mV) to minimize the contribution of I M . Peak I Na was reduced in flecainide by only 4.1Ϯ2% over the drug-free condition (nϭ4, not shown) and did not differ from the effect of a train of subthreshold pulses to Ϫ50 mV (3.3Ϯ0.6%, nϭ4), suggesting that open-state inactivation plays only a minor role under these conditions (ie, 1 mol/L flecainide, the cardiac isoform).
Use-Dependent Block, I M Inactivation, and Brugada Syndrome
The 1795insD mutation enhances occupancy of a slow, inactivated state with intermediate kinetic characteristics (I M ). 6, 7 Here, we show that this gating defect increases the rate at which flecainide block develops during sustained depolarization ( Figure 5A , Table 2 ), delays recovery from flecainide block ( Figure 5B , Table 3 ), and has a net effect to increase use-dependent block (inset, Figure 5B ). Hence, in addition to enhanced closed-state fast inactivation, the I M gating defect induced by 1795insD may doubly sensitize carriers to a Brugada phenotype during flecainide therapy (Figure 1 ). Proarrhythmic flecainide blockade may also be a risk in patients with other Brugada mutations that enhance I M (ie, T1620M). 7 Conversely, additional studies in the LQT3 channels ⌬KPQ (nϭ6), R1644H (nϭ4), and N1325S (nϭ3) revealed no I M inactivation defects (data not shown), suggesting that I M inactivation is not a primary mechanism of flecainide-induced ST-segment elevation in LQT3. 14 Figure 6 proposes a framework for future studies, linking the distinct Na channel inactivation gating defects of LQT3 and Brugada syndrome to the flecainide effects seen in Figures 2 to 5 .
Although flecainide caused a marked slowing of 1795insD recovery, this effect was modest in WT ( Figure 5B ; 1 mol/L flecainide). A previous report using cardiac myocytes described both rapid and slow components of recovery from use-dependent flecainide block with 3 mol/L concentrations, 27 and a marked component of slow recovery was identified in heterologously expressed WT and ⌬KPQ channels exposed to much higher flecainide concentrations (10 to 100 mol/L). 28 The therapeutic plasma concentration of flecainide is 0.2 to 1 g/mL (0.4 to 2 mol/L), 19 however, suggesting that the principal block mechanism at therapeutically relevant concentrations for WT channels is tonic suppression of peak I Na (Figures 3 and 4) . Although previous studies 28 found an IC 50 of 80 mol/L for tonic flecainide block of ⌬KPQ channels, we find a 39.4Ϯ8% (nϭ4) reduction of peak I Na with only 1 mol/L flecainide (holding potential Ϫ100 mV, see legend to Figure 4) . Nonetheless, slow recovery from use-dependent flecainide block may become more significant under conditions that promote I M inactivation (eg, Figure 5B ). It is noteworthy that studies of 
